Comparative Pharmacology
Head-to-head clinical analysis: DOXY 200 versus SUMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOXY 200 versus SUMYCIN.
DOXY 200 vs SUMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Doxycycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the mRNA-ribosome complex, and thus inhibiting peptide chain elongation. It is bacteriostatic and active against a broad range of gram-positive and gram-negative bacteria, as well as atypical organisms.
Tetracycline antibiotic inhibiting bacterial protein synthesis by binding to the 30S ribosomal subunit, blocking aminoacyl-tRNA binding to the A site.
200 mg orally once daily or 100 mg orally every 12 hours.
250-500 mg orally every 6 hours or 500 mg orally every 12 hours (maximum 2 g/day)
None Documented
None Documented
Terminal elimination half-life: 18–22 hours in adults with normal renal function; prolonged in renal impairment (up to 40 hours).
6-12 hours; prolonged in renal impairment (up to 24-48 hours in anuria)
Renal: 40% unchanged via glomerular filtration; Biliary/fecal: 20–25% as active drug and metabolites; remainder as inactive metabolites.
Renal (60-80% unchanged via glomerular filtration), biliary/fecal (20-40%)
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic